最新ニュース Immuneering (NASDAQ:IMRX) 株価情報

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Immuneering Corporation - Class A Common Stock

Immuneering Corp

WIIM

IMRX

Immuneering shares are trading higher after the company released interim data from its Phase 2a trials of IMM-1-104 and IMM-6-415 in advanced RAS and RAF-mutant tumors.

GORO

Gold Resources shares are trading lower after the company announced a $2.5 million secondary offering.

RBC Capital analyst Sean Dodge initiates coverage on Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform rating and announces Price Target of $263.

News

Price Target

Initiation

Analyst Ratings

ICLR

RBC Capital Initiates Coverage On Icon with Outperform Rating, Announces Price Target of $263

UBS analyst Alberto Valerio maintains Copa Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) with a Buy and raises the price target from $160 to $180.

UBS Maintains Buy on Copa Holdings, Raises Price Target to $180

Driven by global expansion, award-winning TVs and streaming devices, and a delightful viewer experience that is the lead-in to all TV
Roku, the #1 selling TV OS in the U.S., Canada, and Mexico&#x2A;, has surpassed 90 million streaming households in the first week of January 2025&#x2A;&#x2A;, a significant milestone as streaming becomes the leading way to watch TV. As the top selling TV OS for over five years in the U.S.&#x2A;&#x2A;&#x2A;, Roku is in nearly half of all U.S. broadband households.

ROKU

Roku Surpasses 90M Streaming Households in Early January 2025, Leading TV OS in US, Canada, Mexico for Over 5-Years

Biotech

General

Immuneering Releases Interim Data From Phase 2a Trials Of IMM-1-104 And IMM-6-415 In Advanced RAS And RAF-Mutant Tumors; Additional Data Expected Q2 2025, Plans To Launch New Phase 2a Arms For Melanoma And NSCLC In Combination With BRAF And Checkpoint Inhibitors

BlackRock's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) short percent of float has fallen 17.56% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 1.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>BlackRock Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736257523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BlackRock has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing BlackRock's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, BlackRock's peer group average for short interest as a percentage of float is 3.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into BlackRock's Recent Short Interest

MPLX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) short percent of float has fallen 7.12% since its last report. The company recently reported that it has 10.59 million shares sold short, which is 2.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MPLX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736257518_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MPLX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MPLX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MPLX's peer group average for short interest as a percentage of float is 4.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MPLX

Peering Into MPLX's Recent Short Interest

Taylor Morrison Home's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) short percent of float has fallen 9.85% since its last report. The company recently reported that it has 2.15 million shares sold short, which is 2.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Taylor Morrison Home Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736257513_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Taylor Morrison Home has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Taylor Morrison Home's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Taylor Morrison Home's peer group average for short interest as a percentage of float is 10.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TMHC

Peering Into Taylor Morrison Home's Recent Short Interest

TCBP

TC BioPharm shares are trading higher on possible continued strength after the company announced yesterday that its listing on the Nasdaq will continue.

Guidance

BTCS

BTCS CEO Charles Allen Issues Investor Letter, Says Co. Surpasses $3.7M Revenue Milestone In 2024, Announces 2025 Targets Up To $20M; Pioneers Publicly Traded Ethereum Infrastructure Focus

STRR

Star Equity shares are trading higher after the company announced its subsidiary received a $3.2 million contract for a multifamily construction project in Maine.

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) fell sharply in today's <a href="https://www.benzinga.com/quote/SLRN">pre-market trading</a>.
ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Acelyrin shares tumbled 15.4% to $2.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) shares fell 13.2% to $7.00 in pre-market trading.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 12.2% to $10.55 in pre-market trading after jumping 32% on Monday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) dipped 7.3% to $8.40 in pre-market trading following a 4% gain on Monday.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 6.8% to $10.41 in pre-market trading.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) fell 3.7% to $7.52 in pre-market trading.</li>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) fell 4.8% to $11.36 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 1.7% to $404.26 in pre-market trading. Tesla on Monday reminisced about delivering the first Model 3 cars made at the company's gigafactory in Shanghai.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

COGT

NPCE

SLRN

THRD

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PMEC

Primtech shares are trading higher after the company announced it secured over $3.8 million in contracts across several economic sectors.

Seasoned Executive to Lead Strategy Across Capital Markets, Partner and Customer Development, and Global Operations
SINGAPORE and SAN DIEGO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Helport AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) ("Helport AI" or the "Company"), an AI technology company serving enterprise clients with intelligent customer communication software, services, and solutions, today announced the appointment of Amy Fong as President and as a director to its board of directors (the "Board"), effective January 1, 2025. Following the appointment of Ms. Fong, the Board will be comprised of 5 directors, 3 of whom are independent.

Management

HPAI

Helport AI Appoints Amy Fong As President And Director, Effective January 1, 2025

Benchmark analyst Christopher Kuhn reiterates Forward Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) from Hold to Hold.

Reiteration

FWRD

Benchmark Reiterates Hold on Forward Airto Hold

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul>
<li>Dividend Yield: 4.14%</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and raised the price target from $25 to $28 on Oct. 30. This analyst has an accuracy rate of 78%.</li>
<li>B. Riley Securities analyst Lee Krowl reiterated a Buy rating and increased the price target from $24 to $25 on Oct. 30. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Dec. 12, Opera declared upcoming cash dividend of 40 cent per share under its recurring dividend program.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"> latest OPRA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="871" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12.png" alt="" class="wp-image-721810" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12-768x726.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</h3>
<ul>
<li>Dividend Yield: 3.23%</li>
<li>Cantor Fitzgerald analyst C J Muse reiterated a Neutral rating with a price target of $125 on Oct. 23. This analyst has an accuracy rate of 68%.</li>
<li>Wedbush analyst Matt Bryson reiterated an Outperform rating with a price target of $150 on Oct. 23. This analyst has an accuracy rate of 80%.</li>
<li>Recent News: On Oct. 22, the company reported first-quarter revenue of $2.17 billion, beating the consensus of $2.119 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">latest STX new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="853" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32.png" alt="" class="wp-image-721811" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32-768x722.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</h3>
<ul>
<li>Dividend Yield: 3.00%</li>
<li>Morgan Stanley analyst Erik Woodring maintained an Equal-Weight rating and increased the price target from $208 to $222 on Dec. 16. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and boosted the price target price target from $235 to $260 on Oct. 24. This analyst has an accuracy rate of 82%.</li>
<li>Recent News: GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) and IBM recently announced a settlement resolving all ongoing lawsuits between the two companies, including claims related to breach of contract, trade secrets, and intellectual property.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to l<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">atest IBM new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33.png" alt="" class="wp-image-721812" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33-768x703.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

OPRA

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields

Palantir Technologies Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock price surged 355% over <a href="https://www.benzinga.com/quote/PLTR/news">the past 12 months</a>, but the shine may be fading as technical indicators and high-profile moves signal potential turbulence ahead.
<h2 class="wp-block-heading">Cathie Conundrum?</h2>
On Monday, Cathie Wood's investment management firm, ARK Invest, <a href="https://www.benzinga.com/25/01/42835519/cathie-woods-monday-moves-dumps-15m-worth-of-hot-stock-palantir-loads-up-amazon-com">offloaded $15 million worth</a> of Palantir stock, totaling 196,728 shares across its flagship ETFs, including ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>).
While Wood remains a long-time supporter of tech disruptors, her pivot toward Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) underscores growing concerns about Palantir&#8217;s valuation. The sale follows <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">Morgan Stanley's recent downgrade</a> to &#8220;underweight,&#8221; slapping a $60 price target on the stock despite its astronomical gains.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42804969/bitcoins-bullish-run-cathie-woods-trades-and-elon-musks-dogecoin-influence-this-week-in-crypto">Bitcoin&#8217;s Bullish Run, Cathie Wood&#8217;s Trades, And Elon Musk&#8217;s Dogecoin Influence: This Week In Crypto</a>
<h2 class="wp-block-heading">Palantir Stock Charts Giving Mixed Signals</h2>
Palantir&#8217;s technical picture paints a tale of two trends. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM.png" alt="" class="wp-image-721685" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM-300x231.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
While the stock's 200-day simple moving average (SMA) at $37.69 screams bullish, shorter-term averages like the eight-day ($77.62) and 20-day ($76.28) SMAs suggest selling pressure. 
The moving average convergence/divergence (MACD) indicator, at a bullish 3.16, offers hope, but the RSI of 54.77 keeps sentiment lukewarm.
<h2 class="wp-block-heading">Market Overhang Or Opportunity?</h2>
Palantir's success in U.S. government contracts and the commercial sector bolsters its growth narrative, but analysts remain divided. Jim Cramer, host of CNBC's Mad Money, <a href="https://www.benzinga.com/markets/equities/25/01/42835613/jim-cramer-predicts-palantir-buying-surge-tonight-after-morgan-stanleys-underweight-rating-unless-another-analyst-starts-with-a-sell">hinted at adding Palantir stock </a>to his portfolio, offering a contrarian view against the bearish sentiment from Morgan Stanley.
Meanwhile, the stock's recent one-month dip of 4.97% signals caution among traders.
With a valuation as polarizing as its investor base, Palantir stands at a crossroads. Bulls point to long-term momentum and a 50-day SMA of $65.73 providing solid support, while bears focus on recent selling pressure and a frothy price tag.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42806417/jim-cramer-works-sunday-brainstorm-on-buying-palantir-and-tesla-stock-calls-them-protective-intellectual-blankets">Jim Cramer Works &#8216;Sunday Brainstorm&#8217; On Buying Palantir And Tesla Stock, Calls Them &#8216;Protective Intellectual Blankets&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

AMZN

ARKK

ARKW

PLTR

Palantir Stock Rally Stalls As Cathie Wood's ARK Invest Sells $15M In Shares

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship deals <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report" rel="noreferrer noopener">with U.K. pharmacies</a>.
Critics argue these arrangements reveal troubling conflicts of interest and highlight gaps in regulating prescription drug advertising.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" rel="noreferrer noopener">Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug</a>
Between 2021 and 2023, Novo Nordisk provided substantial funding to major pharmacy chains such as Boots and Lloyds as well as smaller online clinics.
The sponsorships, valued in the hundreds of thousands of pounds, funded advertising campaigns, pharmacist training and the creation of patient resources.
In return, pharmacies supplied Novo Nordisk with detailed reports on prescription numbers, advertising performance and patient demographics.
While Novo Nordisk insists these sponsorships adhered to industry standards, critics have raised concerns about the ethical implications of such financial ties.
The company's sponsorship practices also drew regulatory scrutiny.
In 2022, Novo Nordisk signed a $119,000 (95,000 pounds) deal with Boots to fund training and advertising for its weight-loss services.
Additional deals with other pharmacies provided free supplies and marketing materials.
However, in October 2024, the UK&#8217;s Prescription Medicines Code of Practice Authority (PMCPA) ruled that these arrangements violated industry codes, citing a lack of partnership independence and inadequate safeguards against incentivizing prescriptions.
Further issues emerged when Novo Nordisk funded online clinics such as the Slimming Clinic and WebMed pharmacy. Both were later found to have illegally promoted prescription-only weight-loss drugs, including Wegovy and Saxenda, on social media.
Posts by the clinics featured images of weight-loss injection pens and direct references to the drugs, violating UK advertising rules.
Novo Nordisk denied knowledge of the clinics' promotional practices and emphasized that its sponsorships were intended for patient education, not marketing.
A 2023 investigation by The Guardian <a href="https://www.theguardian.com/business/2025/jan/04/wegovy-maker-novo-nordisk-sponsored-british-pharmacies-in-pursuit-of-sales" target="_blank" rel="noreferrer noopener">found</a> that nearly 50 companies were reprimanded over similar breaches between January 2023 and September 2024.
In the new year, the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) urged the public to avoid purchasing weight-loss medicines without a prescription from unauthorized sources like beauty salons, social media platforms <a href="https://www.benzinga.com/markets/eurozone/25/01/42772200/dont-buy-weight-loss-medication-from-unauthorized-sources-uk-health-agency-warns-about-risks" target="_blank" rel="noreferrer noopener">or unverified websites</a>.
Price Action: NVO stock is down 1.01% at $84.17 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42841672/stryker-to-buy-inari-medical-for-around-5-billion-to-bolster-position-in-segment-for-venous-thromboembolism" target="_blank" rel="noreferrer noopener">Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

Health Care

Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns

AMST

Amesite shares are trading lower after the company announced a $3.6 million public offering of 1.2 million shares.

Ami Fadia, an analyst from Needham, maintained the Buy rating on Immuneering (IMRX – Research Report). The associated price target remains the same...

Immuneering's Promising Outlook: Strong Clinical Progress and Financial Stability

Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey Hung from Mo...

Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties

Immuneering GAAP EPS of -$0.49

Immuneering Corp. Class A ( ($IMRX) ) has released its Q3 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented to i...

Immuneering Corp. Reports Q3 Loss, Highlights Progress

Morgan Stanley analyst Jeffrey Hung downgraded Immuneering (IMRX) to Underweight from Equal Weight and instituted a base case range of $1-$5 from $...

Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley upgrades PTC, cuts Immuneering, Amicus

Discover today's top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.

Top Trade Picks Of The Day: Don't Miss These Market Movers

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

Mastering Market Chaos: StoryTrading's Top 5 Stocks You Can't Ignore

Immuneering (IMRX) announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, as w...

Immuneering announce data update from Phase 2a trial of IMM-1-104

Immuneering expands lead program after favorable mid-stage data in pancreatic cancer

BYRN

FOLD

IMCR

MARA

MIND

PTCT

RCAT

Press Releases

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Biotech Surges Following Positive Phase 2a Observations

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Earnings

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Launches Pancreatic Cancer Advisory Board

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Comments

Immuneering

ニュース

最新ニュース Immuneering (NASDAQ:IMRX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル